All In Biotech

Free tool

FDA Approval Tracker

Original approvals of brand-name drugs and biologics (NDAs and BLAs) and efficacy supplements, which add a new use, population or dose. Approvals by CBER (most vaccines, blood products and cell and gene therapies) are not in Drugs@FDA and so are missing.

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations

Reset

Matching approvals

59

2023 to 2026

Breakthrough

15

Accelerated

17

Priority review

35

Orphan

33

By year

NDAs and BLAs matching the filters.

  • NDA
  • BLA
View as table
YearNDABLA
202382
2024107
2025145
2026121

59 approvals

Newest first. Hover a badge for what it means.

  • Pimjetmi (Pimicotinib) · Emd SeronoNov 10, 2026
    Original approval · NDA 220414NovelApproval letter

    To treat adults with symptomatic tenosynovial giant cell tumors in whom surgical resection may cause worsening functional limitation or severe morbidity

  • Lyrfigtu (Lirafugratinib Hydrochloride) · ElevarSep 23, 2026
    Original approval · NDA 220425NovelPriority reviewOrphanApproval letter

    To adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 gene fusion or other rearrangement

  • Pixclara (Floretyrosine F-18) · TelixSep 11, 2026
    Original approval · NDA 218592NovelPriority reviewOrphanApproval letter

    To use with positron emission tomography to differentiate recurrent or progressive glioma from treatment-related change in conjunction with other diagnostic evaluations

  • Etcamah (Camizestrant) · AstrazenecaSep 4, 2026
    Original approval · NDA 220359NovelApproval letter

    To treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy

  • Rasonque (Daraxonrasib) · Revolution MedicinesAug 26, 2026
    Original approval · NDA 220910NovelPriority reviewOrphanApproval letter

    To treat metastatic pancreatic cancer

  • Jideytro (Zidesamtinib) · NuvalentJul 22, 2026
    Original approval · NDA 220185NovelOrphanApproval letter

    To treat adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer after receiving a ROS1 kinase inhibitor

  • Revtorpyk (Gedatolisib) · CelcuityJul 14, 2026
    Original approval · NDA 219908NovelPriority reviewApproval letter

    In combination with fulvestran, to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting

  • Cavhanza (Nilotinib) · CycleMay 29, 2026
    Original approval · NDA 217379OrphanApproval letter
  • Decnupaz (Pivekimab Sunirine-Pvzy) · Abbvie INCMay 27, 2026
    Original approval · BLA 761460NovelPriority reviewOrphanApproval letter

    To treat adults with blastic plasmacytoid dendritic cell neoplasm

  • Beqalzi (Sonrotoclax) · Beone Medicines USAMay 13, 2026
    Original approval · NDA 220711NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor

  • Jakafi Xr (Ruxolitinib Phosphate) · Incyte CorpMay 1, 2026
    Original approval · NDA 217180OrphanApproval letter
  • Veppanu (Vepdegestrant) · Rigel PharmsMay 1, 2026
    Original approval · NDA 219835NovelApproval letter

    To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy

  • Evdi (Trabectedin) · ApotexMay 1, 2026
    Original approval · NDA 220837Approval letter
  • Hyrnuo (Sevabertinib) · Bayer HealthcareNov 19, 2025
    Original approval · NDA 219972NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat locally advanced or metastatic non-squamous non-small cell lung cancer with tumors that have activating HER2 tyrosine kinase domain activating mutations in patients who received a systemic therapy

  • Inluriyo (Imlunestrant Tosylate) · Eli Lilly and COSep 25, 2025
    Original approval · NDA 218881NovelApproval letter

    To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, estrogen receptor-1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy

  • Keytruda Qlex (Pembrolizumab, Berahyaluronidase Alfa-Pmph) · Merck Sharp DohmeSep 19, 2025
    Original approval · BLA 761467NovelAccelerated approvalPriority reviewApproval letter

    To treat adult and pediatric (12 years and older) solid tumor indications approved for the intravenous formulation of pembrolizumab

  • Keytruda Qlex (Pembrolizumab, Berahyaluronidase Alfa-Pmph) · Merck Sharp DohmeSep 19, 2025
    Original approval · BLA 761467NovelPriority reviewApproval letter

    To treat adult and pediatric (12 years and older) solid tumor indications approved for the intravenous formulation of pembrolizumab

  • Koselugo (Selumetinib, Selumetinib Sulfate) · AstrazenecaSep 10, 2025
    Original approval · NDA 219943Priority reviewOrphanApproval letter
  • Wayrilz (Rilzabrutinib) · Genzyme CorpAug 29, 2025
    Original approval · NDA 219685NovelOrphanApproval letter

    To treat persistent or chronic immune thrombocytopenia that has not sufficiently responded to immunoglobulins, anti-D therapy, or corticosteroids

  • Hernexeos (Zongertinib) · Boehringer IngelheimAug 8, 2025
    Original approval · NDA 219042NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter

    To treat adults with unresectable or metastatic non-squamous non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received prior systemic therapy

  • Modeyso (Dordaviprone Hydrochloride) · ChimerixAug 6, 2025
    Original approval · NDA 219876NovelAccelerated approvalPriority reviewOrphanApproval letter

    To treat diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy

  • Anzupgo (Delgocitinib) · Leo Pharma AsJul 23, 2025
    Original approval · NDA 219155NovelApproval letter

    To treat moderate-to-severe chronic hand eczema when topical corticosteroids are not advisable or produce an inadequate response

  • Zegfrovy (Sunvozertinib) · DizalJul 2, 2025
    Original approval · NDA 219839NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter

    To treat locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations, as detected by an FDA-approved test, with disease progression on or after platinum-based chemotherapy

  • Ibtrozi (Taletrectinib Adipate) · NuvationJun 11, 2025
    Original approval · NDA 219713NovelBreakthrough therapyPriority reviewOrphanApproval letter

    To treat locally advanced or metastatic ROS1-positive non-small cell lung cancer

  • Brukinsa (Zanubrutinib) · Beone Medicines USAJun 10, 2025
    Original approval · NDA 218785Accelerated approvalOrphanApproval letter
  • Brukinsa (Zanubrutinib) · Beone Medicines USAJun 10, 2025
    Original approval · NDA 218785OrphanApproval letter
  • Emrelis (Telisotuzumab Vedotin-Tllv) · Abbvie INCMay 14, 2025
    Original approval · BLA 761384NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter

    To treat locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression after prior systemic therapy

  • Avmapki Fakzynja CO-Pack (Copackaged) (Avutometinib Potassium, Defactinib Hydrochloride) · Verastem INCMay 8, 2025
    Original approval · NDA 219616NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) after prior systemic therapy

  • Penpulimab-Kcqx (Penpulimab-Kcqx) · Akeso BiopharmaApr 23, 2025
    Original approval · BLA 761258NovelBreakthrough therapyOrphanApproval letter

    In combination with either cisplatin or carboplatin and gemcitabine, to treat adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC), or as a single agent while on or after platinum-based chemotherapy and at least one other prior line of therapy

  • Nilotinib D-Tartrate (Nilotinib D-Tartrate) · CiplaFeb 19, 2025
    Original approval · NDA 218922Approval letter
  • Romvimza (Vimseltinib) · Deciphera PharmsFeb 14, 2025
    Original approval · NDA 219304NovelPriority reviewApproval letter

    To treat symptomatic tenosynovial giant cell tumor for which surgical resection will potentially cause worsening functional limitation or severe morbidity

  • Datroway (Datopotamab Deruxtecan-Dlnk) · Daiichi Sankyo INCJan 17, 2025
    Original approval · BLA 761394NovelApproval letter

    To treat unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease

  • Ensacove (Ensartinib Hydrochloride) · XcoveryDec 18, 2024
    Original approval · NDA 218171NovelApproval letter

    To treat non-small cell lung cancer

  • Unloxcyt (Cosibelimab-Ipdl) · Checkpoint Therapeutics INCDec 13, 2024
    Original approval · BLA 761297NovelApproval letter

    To treat cutaneous squamous cell carcinoma

  • Bizengri (Zenocutuzumab-Zbco) · Merus N.V.Dec 4, 2024
    Original approval · BLA 761352NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat non-small cell lung cancer and pancreatic adenocarcinoma

  • Ziihera (Zanidatamab-Hrii) · Jazz PharmsNov 20, 2024
    Original approval · BLA 761416NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer

  • Danziten (Nilotinib Tartrate) · AzurityNov 7, 2024
    Original approval · NDA 219293Approval letter
  • Vyloy (Zolbetuximab-Clzb) · AstellasOct 18, 2024
    Original approval · BLA 761365NovelPriority reviewOrphanApproval letter

    To treat gastric or gastroesophageal junction adenocarcinoma

  • Itovebi (Inavolisib) · Genentech INCOct 10, 2024
    Original approval · NDA 219249NovelBreakthrough therapyPriority reviewApproval letter

    To treat locally advanced or metastatic breast cancer

  • Lazcluze (Lazertinib Mesylate) · Janssen BiotechAug 19, 2024
    Original approval · NDA 219008NovelPriority reviewApproval letter

    To treat non-small cell lung cancer

  • Voranigo (Vorasidenib) · ServierAug 6, 2024
    Original approval · NDA 218784NovelBreakthrough therapyPriority reviewOrphanApproval letter

    To treat Grade 2 astrocytoma or oligodendroglioma

  • Imdelltra (Tarlatamab-Dlle) · Amgen INCMay 16, 2024
    Original approval · BLA 761344NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat extensive stage small cell lung cancer

  • Rinvoq Lq (Upadacitinib) · AbbvieApr 26, 2024
    Original approval · NDA 218347OrphanApproval letter
  • Ojemda (Tovorafenib) · Day One BiopharmsApr 23, 2024
    Original approval · NDA 217700NovelAccelerated approvalPriority reviewOrphanApproval letter
  • Ojemda (Tovorafenib) · Day One BiopharmsApr 23, 2024
    Original approval · NDA 218033NovelAccelerated approvalPriority reviewOrphanApproval letter

    To treat relapsed or refractory pediatric low-grade glioma

  • Anktiva (Nogapendekin Alfa Inbakicept-Pmln) · Altor Bioscience, LLC, An Indirect Wholly-Owned SuApr 22, 2024
    Original approval · BLA 761336NovelApproval letter

    To treat bladder cancer

  • Lumisight (Pegulicianine Acetate) · LumicellApr 17, 2024
    Original approval · NDA 214511NovelPriority reviewApproval letter

    To use as an optical imaging agent for the detection of cancerous tissue

  • Retevmo (Selpercatinib) · Eli Lilly and COApr 10, 2024
    Original approval · NDA 218160OrphanApproval letter
  • Tevimbra (Tislelizumab-Jsgr) · BeigeneMar 13, 2024
    Original approval · BLA 761232NovelOrphanApproval letter

    To treat unresectable or metastatic esophageal squamous cell carcinoma

  • Ogsiveo (Nirogacestat Hydrobromide) · SpringworksNov 27, 2023
    Original approval · NDA 217677NovelBreakthrough therapyPriority reviewOrphanApproval letter

    To treat adults with progressing desmoid tumors who require systemic treatment

Page 1 of 2Older

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.